by Dom Partridge | Jun 2, 2026 | Industry insights
Written by Paloma Charlesworth Introduction From the 17th–20th May 2026, the Professional Society for Health Economics and Outcomes Research (ISPOR) annual conference took place in Philadelphia, convening stakeholders from across the health economics and outcomes...
by Dom Partridge | Apr 30, 2026 | Industry insights
Written by Kiera Lander & Oliver Burn 1 – A NICE modular update: adopting the EQ‑5D‑5L UK value set What is changing (methods update) The National Institute for Health and Care Excellence (NICE) is consulting on a modular update to adopt the EQ‑5D‑5L dataset...
by Dom Partridge | Mar 31, 2026 | Industry insights
Written by Ben Clark, Paloma Charlesworth, and Kiera Lander This quarterly update highlights recent and upcoming developments shaping the health technology assessment (HTA) environment across Europe, with a particular focus on rare diseases, EU‑level...
by Dom Partridge | Feb 27, 2026 | Industry insights
Written by Jo Wallis, Head of Commercialisation and Pricing Strategy The recent developments put forward by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Food and Drug Administration (FDA) to streamline the regulatory approval processes...
by Dom Partridge | Feb 26, 2026 | Industry insights
Written by Emma Bartram, Associate Systematic Review Analyst A rare disease is one that affects fewer than 1 in 2,000 individuals, and yet 3.5–5.9% of people will experience a rare disease over the course of their lifetime (1,2). Many of these rare conditions...
by Dom Partridge | Dec 9, 2025 | Industry insights
By Toby Hobbs Changes to NICE ICER thresholds confirmed NICE has announced that from April 2026 there will be an increase to its cost-effectiveness threshold. This marks one of the biggest shifts in UK Health technology assessment (HTA) practice in years and...
